Hilde Windels has close to 23 years of experience in the Biotechnology Life Sciences industry, primarily in CFO, investor relations-fundraising and general management roles. After a career of 12 years with ING, she decided in 1998 to join Devgen, at that time a biotechnology company in its start-up phase.Between 2009 and 2011 she was an independent consultant, providing CFO-services for Seps Pharma, Tigenix and Pronota. In 2011 she started at Biocartis where she has been CFO, deputy CEO and interim CEO. In 2017 she became CEO of MyCartis, a spin out of Biocartis. After that, she became CEO of Antelope Dx in 2019, a spin out of MyCartis. Since September 2021, she is an advisor in the life sciences industry and board member. She is currently a member of the boards of MDx Health, Phaxiam, Celyad, Microphyt and GIMV. Hilde Windels graduated as a Commercial Engineer (applied economics) from the Catholic University of Leuven.